DNDi E-news - Scientific Update
September 2014   |   View Online

Learning to deliver: Challenges in NTD drug research and development

 

Viewpoint by Graeme Bilbe, Research & Development Director, DNDi


DNDi and other not-for-profit drug research and development (R&D) organizations have explored new R&D pathways to develop and deliver safe, adapted, and affordable treatments for neglected diseases. Most of these new pathways have shown signs of success, while several have faced challenges that span across the drug discovery and development processes. »

R & D Status September 2014

 
Human African Trypanosomiasis
The two promising oral drug candidates fexinidazole and SCYX-7158 continue to progress in clinical development. »

Leishmaniasis
Combination treatments now tested co-infected HIV/VL patients in  Ethiopia and policy change in the Indian revised national kala-azar elimination roadmap. »

Chagas disease
The new chemical entity fexinidazole now tested in Bolivia adults with chronic intermediate Chagas disease. »

Filarial diseases
Identification and progression through preclinical testing of a macrofilaricide. »

Paediatric HIV
Preparation of an implementation study in Africa using a PI-based treatment with existing LPV/r-based solid formulations used in combination with NRTI dispersible tablets. »

Malaria
320 million of ASAQ FDC distributed since 2007. »

NEW Videos

 

Chagas Disease:
A Silent Emergency

Watch video »

 
 
The Mark of Neglect:
Cutaneous Leishmaniasis

Watch video »

 

Publications


Journal of Biomolecular Screening
Chagas Disease Drug Discovery: Toward a New Era »

PLOS NTDs

Innovative Approaches to Clinical Data Management in Resource Limited Settings Using Open-Source Technologies »

Expert Review of Anti-infective Therapy:
Treatment options for second-stage gambiense human African trypanosomiasis »

Africa Health:
From famine to feast: the transformation of the ACT malaria treatment landscape since 2004 »

PLOS NTDs:
Visceral leishmaniasis and HIV coinfection in the Mediterranean region »

PLOS NTDs:
How far are we from visceral leishmaniasis elimination in Bangladesh? An assessment of epidemiological surveillance data »

PLOS NTDs:
Synergy Testing of FDA-Approved Drugs Identifies Potent Drug Combinations against Trypanosoma cruzi »

Developing World Bioethics:
Improving the quality of host country ethical oversight of international research: the use of a collaborative ‘pre-review’ mechanism for a study of fexinidazole for human African trypanosomiasis »
EN ESPAÑOL
EM PORTUGUÊS
PORTFOLIO - JUNE 2014


 
EVENTS

1st LEAP Conference & 21st LEAP Meeting
Bahir Dar, Ethiopia
29 Sep - 1 Oct 2014

 
JOBS
DNDi IN THE MEDIA

Sciences au Sud: 'En dix ans, six nouveaux médicaments' - Interview: Bernard Pécoul

Speaking of Medicine - PLOS Medicine Community Blog: "Who Should Contribute to Funding of Global Health R&D and How Much?"

Veja: "Estudo com novo medicamento contra doença de Chagas avança para segunda fase"

El Economista: "Nueva esperanza contra el mal de Chagas" - "New hope against Chagas disease"  

Deutschlandfunk: "Vernachlässigte Krankheiten: Heilung für alle"

The Atlantic: "Northern Virginia: 'Ground Zero' for Kissing Bug Disease"

AIDS 2014 Blog: "Now or Never: The Urgency of Closing the Treatment Gap for Children Living with HIV/AIDS"
Follow us on social media:
Twitter Facebook LinkedIn YouTube
Visit our websites:
DNDi.org  DNDiAL.org  DNDiNA.org  DNDiJapan.org  
Copyright © 2014 Drugs for Neglected Diseases initiative (DNDi), All rights reserved.
You are receiving this email because you are part of DNDi's network. You have the option to unsubscribe.

Our mailing address is:
Drugs for Neglected Diseases initiative (DNDi)
15 ch. Louis-Dunant
Geneva 1202
Switzerland

Add us to your address book


unsubscribe from this list    update subscription preferences